Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
From “space-as-a-service” niche player to SHIELD radar contributor: what changed for Sidus Space after our first deep dive, how the December 2025 capital raise reshaped the runway, and why LizzieSat-4 plus AI/ML payloads make 2026 a crucial execution year.
SeaStar Medical is not a typical “pre-clinical biotech on a slide deck”. The company has already crossed the line into real-world use: QUELIMMUNE (the pediatric implementation of the SCD) is approved by the US Food and Drug Administration via HDE and has been adopted by a growing group of leading US children’s hospitals. Early registry data suggest improved survival and kidney recovery in some of the sickest patients in the ICU, with no device-related safety signals reported so far
We wrote our original bullish editorial at the very end of December 2025, when the stock was still trading around five dollars and largely under the radar. January brought ASCO GI pancreatic data, a first PMA module to the FDA, a shareholder letter and a sharp re-rating. Here we revisit the thesis, check the fundamentals and map the next catalysts. Educational only, not investment advice.
Castellum starts 2026 with exactly what you want to see in a micro-cap defense name: more work, bigger visibility inside the U.S. missile-defense and Navy ecosystem, and a tape that already gave traders a clean spike-and-fade on the first new contract of the year.
January 2026 has been anything but quiet for POET Technologies. The stock first extended the late-2025 rerating on the “AI optics” narrative and then got hit hard by a US$150 million registered direct offering that erased most of the month’s gains. The industrial thesis around the Optical Interposer has not changed, but the share count has – and the market is repricing that.
Allogene Therapeutics is not the 2+ billion dollar hype story it was a few years ago. After the initial enthusiasm around off-the-shelf CAR T, the stock has been crushed by a sequence of events: an FDA clinical hold in 2021, years of execution risk, pipeline reshuffling and workforce reductions.
In mid-January we covered BNAI as a tiny, risky AI play with a handful of real enterprise projects and a fragile balance sheet. Two weeks later the stock has printed a 52-week range from $1.18 to an intraday high above $80, short interest has exploded, and the company rushed out multiple press releases on licensing, warrant exercises, debt conversion and a premium private placement. This note is meant to put everything back into one framework: what BEN actually does, what changed in January, how stretched the valuation looks, and which hard catalysts matter once the trading dust settles.
Deep dive on Palantir’s dual engine (government + commercial AI), the new U.S. Army Enterprise Agreement and the Innodata partnership for multimodal data in “rodeo analytics” – with an eye on 2026 catalysts.
A few years ago, the Amarin story was dominated by a single word: generics. After losing key patent battles on Vascepa, the U.S. business was hit by an aggressive wave of skinny-label competitors, PBM exclusions and net price pressure, to the point where many investors simply filed AMRN under “broken story”. At the start of 2026, the picture is no longer that binary. The company is still far from the glory days, but the trajectory is clearly different: less bleeding, more structure, and a gradual shift from survival mode to controlled recovery.
REGAL Survival Clock, SLS009 Momentum and the Waiting Game
Monthly recap on SELLAS Life Sciences: what changed since the December update, how the 72/80 events in the REGAL Phase 3 trial reshaped the narrative, and which catalysts traders are watching next.
From 48-week IMPACT data and a CEO switch to FDA Breakthrough status, a 75M$ raise and a +50% month: how the Altimmune story and the tape have changed in a few weeks
Since the last Merlintrader pieces on ImmunityBio, the story has accelerated on several fronts. Anktiva net product revenue exploded to a preliminary 113 million dollars for 2025, a roughly 700 percent year-over-year jump with 38.3 million in the fourth quarter alone, backed by strong unit growth and broader coverage in the United States and abroad, as detailed in the company’s mid-January 2026 update and echoed across financial coverage.
Week Ahead and Recap – January 31, 2026
Gold near record highs, AI shockwaves in gaming, and a cluster of high-grade biotech catalysts from DF-003 in ROSAH syndrome to camizestrant in ESR1-mutant breast cancer. This is your condensed map for the week.
SKYX wants to turn the ceiling into the “brain” of the home: a plug & play outlet that makes lights, fans and smart devices safer and easier to install, plus an AI-native platform built on NVIDIA’s cloud ecosystem. Revenues have climbed to record levels through Q3 2025 and the company has just secured new strategic and institutional funding ahead of big launches at Lowe’s and early smart city deployments.
The core of the Protalix model today is Elfabrio (pegunigalsidase alfa) for Fabry disease, commercialized globally by Chiesi under the two Chiesi agreements described in the FY 2024 release and 10-K. :contentReference[oaicite:2]{index=2} Protalix manufactures the drug substance in Carmiel and sells finished product to Chiesi, receiving tiered payments in the 15–35% ex-US and 15–40% US range on average selling price, linked to purchased volumes, as outlined in the “Chiesi Agreements” and “Revenues from selling goods” sections.
Real-time news feeds (RTTNews, MarketScreener, StockTitan, QuiverQuant) and broker dashboards show VIVS up roughly +70–100% in pre-market trading on 30 January 2026, with pre-market prices around 3.0 USD and, in some snapshots, higher peaks depending on the exact timestamp. Versus a previous close of 1.70 USD, this is a classic microcap “gap & squeeze” setting, driven by a mix of genuine news and positioning on a very small float.
Deep dive (as of January 30, 2026) on Kyverna Therapeutics (KYTX): autologous CD19 CAR-T mivocabtagene (miv-cel, KYV-101) in autoimmune diseases, positive registrational KYSA-8 data in stiff person syndrome (SPS), RMAT/Fast Track designations, 2026 BLA ambitions and cash runway into 2027. Educational only, not investment advice
Tiziana Life Sciences is building an entire company around one idea: that intranasal delivery of a fully human anti-CD3 antibody, foralumab, can re-educate the immune system and cool down chronic neuroinflammation without broad systemic immunosuppression.
Quince Therapeutics (QNCX) released topline results from its pivotal Phase 3 NEAT clinical trial of eDSP (EryDex) in Ataxia-Telangiectasia, a rare pediatric neurodegenerative and immunodeficiency disorder. The press release confirms that the study did not meet its primary endpoint on the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS), with insufficient separation versus placebo despite prior Phase 2 and ATTeST signals
Intuitive Machines is a Houston-based space infrastructure company working on lunar landers, cislunar communications and defense-focused satellite platforms. The stock is one of the purest public plays on the Artemis + Golden Dome “space infrastructure” theme.